This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.

CLINICAL FOCUS

PATRICIA DONAHUE BALDWIN, RN, MS, OCN® Associate Editor

Herpes Zoster

Patricia Donahue Baldwin, RN, MS, OCN®

Definition

- A. Herpes zoster is an acute viral skin infection that results from reactivation of the varicella-zoster virus (VZV) in sensory dorsal root ganglia.
- B. Herpes zoster is characterized by unilateral vesicular eruption and neurologic pain in a dermatomal pattern (see Figure 1).
- C. The condition commonly is referred to as "shingles" or "zoster."

Incidence

- A. Six hundred thousand to one million cases appear each year in the United States.
- B. Incidence rates increase with advancing age and double in each decade past 50 years.
- C. The condition is uncommon in individuals under 15 years of age.
- D. The condition is less common in African Americans, indicating a possible racial difference in susceptibility to VZV reactivation.
- E. Current evidence suggests the possibility of decreased reactivation of VZV following varicella vaccination.

Risk Factors

- A. Factors that decrease cell-mediated immunity increase the risk of herpes zoster.
- B. Age and disease-related factors1. Age (older than 50)
 - Alignancies (especially lymphoproliferative disorders such as non-Hodgkin's lymphoma)
 - 3. HIV/AIDS
- C. Treatment-related factors1. Organ or allogeneic bone marrow

transplants (occurring secondary to immunosuppressive medications)

- 2. Systemic corticosteroid use
- 3. Chemotherapy
- 4. Radiation therapy

Pathophysiology

- A. After initial infection with varicella (i.e., chicken pox), VZV is not eliminated from the body. Instead, VZV remains dormant in the sensory dorsal root ganglia.
- B. Cell-mediated immunity maintains dormancy.
- C. Decreased cell-mediated immunity may cause reactivation of the dormant virus, resulting in herpes zoster.
- D. Reactivated virus then follows the sensory nerve pathway, causing pain and skin lesions in the area innervated by the sensory nerve (dermatome).
- E. Transmission of VZV is possible to those without immunity (i.e., no prior history of primary varicella infection or varicella vaccination).
 - 1. Active virus is present in vesicles.
 - 2. Herpes zoster is less contagious than chicken pox.
 - *a)* Approximately 15% household infection rate is reported.
 - *b)* Transmission causes chicken pox in those infected.

Signs and Symptoms

- A. Prodromal symptoms usually precede eruption of lesions by one to five days, occasionally by as much as three weeks.
 - 1. Fever
 - 2. Malaise
 - 3. Headache

- 4. Pruritis
- 5. Pain is the most common symptom and is manifested as:
 - *a*) Burning or lancinating dysethesia
 - b) Paresthesias
 - *c)* Hyperesthesia (increased sensitivity to stimuli such as touch and temperature)
 - d) Occasionally, the characteristic rash does not develop after prodromal symptoms. This syndrome is known as zoster sine herpete.
- B. Rash
 - Initially, a maculopapular rash that follows a dermatomal, or belt-like, distribution appears.
 - 2. This rash progresses to clusters of clear vesicles or bullae on an ery-thematous base.
 - a) Lesions usually are unilateral.
 - b) They rarely cross the midline.
 - *c)* Lesions can occur in scattered patches or a continuous band.
 - *d)* New vesicles continue to erupt for two to three days.
 - Lesions become pustular, occasionally hemorrhagic, and crust over within 7–14 days.
 - No active virus is present in crusted lesions.
 - 5. Total resolution of rash occurs in three to four weeks.
 - 6. Residual areas of hyperpigmentation, hypopigmentation, or scarring may occur.

Patricia Donahue Baldwin, RN, MS, OCN®, is an oncology clinical nurse specialist at VA Boston Healthcare System in Boston, MA.

Digital Object Identifier: 10.1188/02.CJON.55-58

